# M2.5 — External Review Engagement Package (DRAFT — prepared, auditor OUTSTANDING)

**Authorized:** By Elmahrosa-Teos (Founder), dated directive 2026-09-13 ("do it on my behalf").
**Baseline under review:** A3 baseline tag `qss-a3-locked-r2` @ `5816117`; Phase 0 artifacts (`a1ca8dc`); Phase 1 acceptance (`dcc65b6`).
**Governance constraint:** Milestone 2.5 (FINAL_ORDER.md §4) requires a **named reviewer with cryptographic engineering/security expertise** producing a **signed, dated deliverable**. This package is the engagement paperwork; it does **not** constitute the review. The auditor name is explicitly **OUTSTANDING** and must never be assumed or invented.

---

## 1. Engagement scope

Review the Teos Quantum-Safe Stack A3 baseline for:

1. Cryptographic standards alignment (FIPS 203 / 204 / 205, SP 800-90B/C, SP 800-57 Pt 3, SP 1800-38).
2. Interface correctness and implementability (zero live crypto today — review the *design* and *stub contract*).
3. Security & privacy properties (fail-closed, constant-time comparisons, secret zeroization).
4. Compliance mapping accuracy (TESL, EU AI Act Art. 50, NIST SP 800-53, PCI DSS, HIPAA, GDPR).
5. CBOM / CycloneDX 1.6 conformance and threat-model completeness.

## 2. Required qualifications (selection criteria)

- Demonstrated cryptographic engineering or applied security expertise (published work, certifications, or verifiable practitioner history in this domain).
- Independence from the authoring session (no AI-authored auditor identity).
- Availability for a dated deliverable + disposition exchange.

## 3. Evidence bundle (index)

| Evidence | Path |
|---|---|
| Program charter | `FINAL_ORDER.md` |
| Cryptography inventory (0.1) | `docs/quantum-safe-stack/inventory/0_1_current_crypto_inventory.md` |
| CBOM (0.2, schema-valid) | `docs/quantum-safe-stack/inventory/quantum-inventory.cbom.json` |
| Threat model (0.3) | `docs/quantum-safe-stack/A3_THREAT_MODEL.md` |
| Common contract (A2) | `modules/quantum-safe/COMMON-CONTRACT.md` |
| Phase 1 acceptance evidence | `docs/quantum-safe-stack/phase1_acceptance.md` |
| NIST alignment reports (2.1) | `docs/quantum-safe-stack/validation/nist/*` |
| CycloneDX conformance (2.2) | `docs/quantum-safe-stack/validation/cyclonedx/*` |
| Security properties (2.3) | `docs/quantum-safe-stack/validation/security/*` |
| Compliance mapping (2.4) | `docs/quantum-safe-stack/validation/compliance/*` |
| M2.5 checklist | `docs/quantum-safe-stack/M2_5_EXTERNAL_REVIEW_CHECKLIST.md` |

## 4. Deliverable template

```
REVIEWER NAME / ORGANIZATION: <named auditor — OUTSTANDING>
SIGNATURE: <dated signature>
BASELINE REVIEWED: <commit sha>
SCOPE: <per §1>
FINDINGS: FEEDBACK-ID-XXX → ACCEPTED / CONDITIONAL / REJECTED
DISPOSITION: recorded in A3_FEEDBACK_AND_RESPONSES.md
CONCLUSION: RECOMMEND ACCEPT / CONDITIONAL / NOT READY
```

## 5. Disposition process

Findings land in `docs/quantum-safe-stack/A3_FEEDBACK_AND_RESPONSES.md`; each is dispositioned with an owner and deadline. **Critical** findings must be addressed before Phase 2 closure per FINAL_ORDER §4 exit gate.

## 6. Status

- Engagement package: ✅ PREPARED (2026-09-13).
- Independent Reviewer fields (structural template — all values OUTSTANDING):
  - **Independent Reviewer:** [PLACEHOLDER — Full legal name] — [PLACEHOLDER — Organization / Independent Reviewer]
  - **Qualifications & Independence:** [PLACEHOLDER — CV / certification / professional profile URL]. Reviewer confirms relevant technical/security expertise and independence from the development team.
  - **Deliverable:** Signed independent review report, including findings, severity classification, evidence, and recommendations.
  - **Deadline:** [PLACEHOLDER — Signed final review report due: DD Month YYYY]
- Rule 6: **UNSATISFIED** — no named auditor; the three real values must be supplied by the Founder and the signed-review requirement formally recorded before any completion claim.
- Auditor: **🔴 OUTSTANDING — must be named by the Founder.** No signed report exists. Phase 2 remains IN PROGRESS — INTERNAL ONLY; no completion claim is made.